Hi! Dr Weinstein, Is it now official that Eculizumab is approved in Ontario for treatment of aHUS, would OHIP only patients (without private insurance) benefit, does one have to establish the compliment mutations to be an eligible candidate.
Hi Venkat,
According to the company, although the drug is indeed approved for usage in aHUS, coverage is determined on a case-by-case basis. And no, approval does not depend on the demonstration of a mutation; demonstrable mutations are often absent in aHUS in 30-50% of cases, making the diagnosis a combination of both clinical and laboratory parameters.
Jordan
According to the company, although the drug is indeed approved for usage in aHUS, coverage is determined on a case-by-case basis. And no, approval does not depend on the demonstration of a mutation; demonstrable mutations are often absent in aHUS in 30-50% of cases, making the diagnosis a combination of both clinical and laboratory parameters.
Jordan
- Page :
- 1
There are no replies made for this post yet.
